Drug Detail:Auvelity (Bupropion and dextromethorphan)
Generic Name: DEXTROMETHORPHAN HYDROBROMIDE 45mg, BUPROPION HYDROCHLORIDE 105mg
Dosage Form: tablet, multilayer, extended release
Drug Class: Miscellaneous antidepressants
Drug Detail:Auvelity (Bupropion and dextromethorphan)
Generic Name: DEXTROMETHORPHAN HYDROBROMIDE 45mg, BUPROPION HYDROCHLORIDE 105mg
Dosage Form: tablet, multilayer, extended release
Drug Class: Miscellaneous antidepressants
Prior to initiating and during treatment with AUVELITY:
The recommended starting dosage of AUVELITY (45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride) is one tablet once daily in the morning. After 3 days, increase to the maximum recommended dosage of one tablet twice daily, given at least 8 hours apart. Do not exceed two doses within the same day.
Administer AUVELITY orally with or without food [see Clinical Pharmacology (12.3)]. Swallow tablets whole, do not crush, divide, or chew.
The recommended dosage of AUVELITY for patients with moderate renal impairment (eGFR 30 to 59 mL/minute/1.73 m2) is one tablet once daily in the morning [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
The recommended dosage of AUVELITY when co-administered with strong CYP2D6 inhibitors is one tablet once daily in the morning [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].
The recommended dosage for patients known to be poor CYP2D6 metabolizers is one tablet once daily in the morning [see Use in Specific Populations (8.8), Clinical Pharmacology (12.3)].
At least 14 days must elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with AUVELITY. Conversely, at least 14 days must be allowed after stopping AUVELITY before starting an MAOI antidepressant [see Contraindications (4), Drug Interactions (7.1)].